Updates are available Correction dated 2024-08-24

Article History

Accepted: 20 May 2024

First Online: 7 June 2024

Change Date: 24 August 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11912-024-01590-x

Declarations

:

: The authors declare no competing interests.

: • Andrea Necchi: Honoraria: Roche, MSD, AstraZeneca, Janssen, Foundation Medicine, BMS, Astellas. Consulting or Advisory role: MSD, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics/Astellas, Bristol-Myers Squibb, Rainier Therapeutics, Bycicle Therapeutics, GlaxoSmithKline, Basilea Pharmaceutica, Catalym. Research Funding (Institution): MSD, AstraZeneca, Ipsen, Gilead. Travel, Accommodations, Expenses: Roche, MSD, AstraZeneca, Janssen, Rainer Therapeutics, Pfizer. Employment and Stock Ownership (spouse): Bayer.• Ashish M. Kamat: Grants or Contracts: FKD Therapies (now Ferring), Patient-Centered Outcomes Research Institute (PCORI), Photocure, Seagen, EnGene, Arquer Diagnostics, SWOG; Advisory Board/Consulting Fees: Astellas Pharma, BiologicalDynamics, Bristol-Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Imagin Medical, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sessen Bio, Theralase, Urogen Pharma, US Biotest, Vivet Therapeutics; Patents, CyPRIT (Cytokine Predictors of Response to Intravesical Therapy)-Joint patent with MD Anderson CancerCenter; Leadership or fiduciary role in other board, society, committee or advocacy group: European Urology Oncology; International Bladder CancerGroup (IBCG); International Bladder Cancer Network (IBCN); Journal of Urology; UroToday.• Philippe E. Spiess: no financial disclosures to report, only leadership positions: president of the Global Society of Rare Genitourinary Tumors, vice-chair of the NCCN bladder and penile cancer panel, member of the ASCO/EAU panel on penile cancer.• Antonio Cigliola: nothing to disclose.• Li Roger: Research support: Predicine; Veracyte; CG Oncology; Valar labs; Merck; Clinical trial protocol committee; CG Oncology; Merck; Janssen; Scientific advisor/consultant: BMS, Merck, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence, CG Oncology, Janssen, Thericon; Honoraria: SAI MedPartners, Solstice Health Communications, Putnam Associates, UroToday.• Karima Oualla: Honoraria, consulting or advisory boards: Roche, MSD, Pfizer, Janssen, Astellas, Astrazeneca, Mylan, Ipsen, Novartis, Hikma, Sothema, SunPharma. Research funding (Institution): Roche.• Gagan Prakash: nothing to disclose.• Gupta Shilpa: Serve(d) as a consultant for: Seattle Genetics; Merck; EMD Serono; Bristol Myers Squibb; Pfizer; Gilead; Serve(d) as a speaker or a member of a speakers bureau for: Seattle Genetics; Gilead; Janssen; Received research grant from: (Institution) Bristol Myers Squibb; Merck; EMD Serono; Moderna; Gilead; Seagen.• Jad Chahoud: Research funding to his institution: US Department of defense (DOD), the state of Florida and Pfizer; Advisory and consulting fees: Aveo, Exelixis, Eisai, Pfizer and MyCareGorithm.